(Total Views: 664)
Posted On: 08/12/2020 5:27:27 PM
Post# of 145875
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Re: nmbr1stckpckr #48936
Agreed. This is VERY positive news. If you are underwhelmed, your expectations are unrealistic.
1) We are requesting EUA in several countries including our own.
2) If we have to do a phase 3, it will be small and will enroll quickly.
3) CD12 Interim results are 45-60 days out and I believe is a show in for EUA approval.
4) No other drug has shown any efficacy in the M2M group.
5) M2M is likely the most difficult group to show efficacy in. S/C will be a slam dunk.
6) CYDY is getting ready to launch more trials, and is bringing in experts in various fields to assist.
7) Uplisting is progressing. Audited financials complete this week.
Top line data sent to Media and Big pharma today
I couldnt be happier with how thing are progressing.
1) We are requesting EUA in several countries including our own.
2) If we have to do a phase 3, it will be small and will enroll quickly.
3) CD12 Interim results are 45-60 days out and I believe is a show in for EUA approval.
4) No other drug has shown any efficacy in the M2M group.
5) M2M is likely the most difficult group to show efficacy in. S/C will be a slam dunk.
6) CYDY is getting ready to launch more trials, and is bringing in experts in various fields to assist.
7) Uplisting is progressing. Audited financials complete this week.
![8) 8)](smileys/bigeyes.gif)
I couldnt be happier with how thing are progressing.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)